Original Research J Clin Psychiatry March 2026

Temporal Dynamics of Antidepressant Response Following Brexanolone Treatment in Postpartum Depression

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary Postpartum depression can impair maternal functioning, affect infant well-being, and is a leading cause of maternal death in the first year postpartum. For clinicians considering rapid-acting neuroactive steroid treatment, this study offers a close look at how quickly symptoms, anxiety, anhedonia, rumination, and maternal functioning changed during and after brexanolone treatment. FAQ How quickly did women with postpartum depression respond to brexanolone in this study? 10 questions
Key Takeaways In this open-label pilot, all 10 participants met HAMD response criteria by H72, 60% achieved response by H24, and 80% achieved remission by H48, with remission sustained at D30 for all 9 subjects who remitted during treatment. 6 takeaways Clinical Guide How should clinicians identify appropriate candidates for brexanolone infusion and monitor them during treatment for postpartum depression? 8 steps Clinical Guide How should clinicians monitor symptom change during rapid recovery from postpartum depression during brexanolone treatment? 8 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Live Webinar
and Q&A With
Dr Deligiannidis

JULY 16 · REGISTER NOW
Webinar ad featuring Dr. Kristina M. Deligiannidis on PPD treatment options

Subscribe to read
more articles

Subscribe